MARIA CARDENAS: Open Payments
NPI 1700307337 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$690 in 31 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $74 · 2025 $690
Food & beverage: $588Education: $101
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $227 |
| ABBVIE INC. | 6 | $120 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $117 |
| Alkermes, Inc. | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Lundbeck LLC | 2 | $39 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Indivior Inc. | 1 | $15 |
Products named: VRAYLAR, CAPLYTA, REXULTI, UZEDY, AUSTEDO XR, ARISTADA, INGREZZA, VIVITROL.
Industry payments across CO — which companies pay providers there.
